CPI Antitrust Chronicle Guest Article: FTC v. Actavis: Has the Dust Really Settled?


Three months now have passed following the Supreme Court's decision in FTC v. Actavis, 133 S. Ct. 2223 (2013), which subjects to "rule of reason" antitrust scrutiny certain pharmaceutical patent settlements involving a cash payment by the branded drug company to the generic drug company. With the benefit of time and hindsight we can say two things are certain: First, litigants and courts are struggling to construct a framework to implement the Court's holding. Second, the narrow parameters of Actavis invite continued attacks on pharmaceutical patent settlements where value other than cash payments is exchanged.

These two developments create a level of uncertainty that will forestall the objectives of the Hatch-Waxman Act and, derivatively, impact and delay competition in the pharmaceutical industry until resolved.

Excerpted from the CPI Antitrust Chronicle, September 30, 2013. To read the full article, click on the PDF linked below.

PDF - FTC-v-Actavis_Ripley-Musgrove.pdf

Email Disclaimer